Extended Data Fig. 5: Validation of piperacillin-tazobactam’s effect on enriching oral bacteria in feces using an independent pediatric allo-HCT cohort. | Nature Microbiology

Extended Data Fig. 5: Validation of piperacillin-tazobactam’s effect on enriching oral bacteria in feces using an independent pediatric allo-HCT cohort.

From: Oral bacteria relative abundance in faeces increases due to gut microbiota depletion and is linked with patient outcomes

Extended Data Fig. 5

19 children (1–17 year old, 10.1 year old on average) were treated with either oral polymyxin-neomycin or oral piperacillin-tazobactam in the Leiden University Medical Center, Netherlands. Both medications were administered 10 days before transplantation until engraftment or 21 days after transplantation, whichever occurred later. Samples were grouped into four transplantation stages. FDR-corrected P values were calculated using a one-sided Mann-Whitney U test. Box plots represent the median, 25th and 75th percentiles and whiskers represent the 95th and 5th percentiles.

Back to article page